Abstract 380P
Background
Globally, there are roughly 476 million indigenous peoples in 90 nations worldwide, representing a wide range of cultures, dialects, and spirits. India has the world's second-highest concentration of tribal people after African countries. Spread across 705 tribes accounting for 8.6% of the country’s population, over 104 million tribal people live; making India home to numerous tribes with diverse origins, customs, and societal practices. Government of India have identified Primitive tribal communities on the basis of their pre-agricultural level of technology, extremely low level of literacy, and small, stagnant, or diminishing population. This epidemiological cross- sectional study was designed to assess the prevalence of oral cancer and its awareness among Irula tribes of South India.
Methods
A cross sectional descriptive study was conducted among 200 Irula tribes using a pretested Questionnaire, which included demographic information, tobacco habits, its frequency, and cancer awareness. Oral examination to assess oral cancer was done by a single examiner. SPSS version 21 was used to analyse the collected data.
Results
The findings revealed that 87% of the 200 study participants had no formal education and 38% had never visited a dentist. 64.5% practised indigenous brushing. There were 52% of oral mucosal lesions and 6% of malignant oral tumours found. This community had a very high prevalence of periodontal disease, tobacco chewing, and deeply ingrained beliefs and customs about dentition and dental treatment. The prevalence of oral mucosal lesions in the study population was due to tobacco use and a lack of knowledge about the harmful effects of the products used.
Conclusions
Although the problems associated with smoking and chewing tobacco are extensively documented in the literature, it is worrying that this indigenous group is not aware of the consequences. The public should be made aware of these concerns, especially those in high-risk groups, according to health specialists.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract
251P - LDH isozyme as a prognostic factor for patients with metastatic clear cell renal cell carcinoma (mCRCC)
Presenter: Hayato Takeda
Session: Poster Display
Resources:
Abstract
252P - Risk factors for recurrence after curative nephrectomy in non-metastatic renal cell carcinoma: A retrospective cohort study
Presenter: Kristine Tejada
Session: Poster Display
Resources:
Abstract
253TiP - WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma: A phase II multi-center study
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
254TiP - Prospective observational trial of cabozantinib plus nivolumab in Japanese patients with advanced or metastatic renal cell carcinoma: JACUMET trial
Presenter: Yuji Miura
Session: Poster Display
Resources:
Abstract
264P - Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Chia-Chi Lin
Session: Poster Display
Resources:
Abstract
266P - Clinical application and potential impact of liquid biopsy on the management of Chinese patients with metastatic castration-resistant prostate cancer (mCRPC): A territory-wide prospective analysis
Presenter: Wai Kay Philip Kwong
Session: Poster Display
Resources:
Abstract
267P - Exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancer
Presenter: Diwei Zhao
Session: Poster Display
Resources:
Abstract
268P - Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study
Presenter: Hou In Chou
Session: Poster Display
Resources:
Abstract
269P - Prostate cancer harboring low COMT expression correlates with a poor prognosis and response to enzalutamide
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract